VANCOUVER, June 6 /CNW/ - QLT Inc. (NASDAQ: QLTI; TSX: QLT) announced
today that Health Canada has completed its review of QLT USA, Inc.'s labeling
supplement (SNDS) for Aczone(R) and has removed the glucose-6-phosphate
dehydrogenase (G6PD) screening and blood monitoring requirements.
